Arcus Biosciences

Yahoo Finance • 7 days ago

How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eisai’s updated analyst model now points to a fair value price target of ¥5,076.92, compared with the prior ¥5,009.23, givi... Full story

Yahoo Finance • 23 days ago

Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer

Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30.... Full story

Yahoo Finance • last month

Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD

In April 2026, Arcus Biosciences said Gilead Sciences chose not to make a continuation payment, ending option rights to several early-stage Arcus programs while keeping time-limited options on select assets like AB801, AB598, AB102 and a T... Full story

Yahoo Finance • 2 months ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story

Yahoo Finance • 3 months ago

Arcus Biosciences Q4 Earnings Call Highlights

Arcus Biosciences logo Key Points Updated ARC-20 single-agent data show casdatifan (100 mg QD) with a confirmed ORR rising to 45% and median PFS of 15.1 months, which Arcus says compares favorably to belzutifan in late-line ccRCC. Phase... Full story

Yahoo Finance • 3 months ago

Here’s What Analysts Think About Arcus Biosciences (RCUS)

Arcus Biosciences, Inc. (NYSE:RCUS) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Arcus Biosciences, Inc. (NYSE:RCUS) was downgraded to Equal Weight from Overweight at Wells Fargo, with the firm b... Full story

Yahoo Finance • 3 months ago

GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales

Gilead Sciences, Inc. GILD reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.86, which beat the Zacks Consensus Estimate of $1.83. The bottom line was down from $1.90 reported a year ago. The year-over-year decrease was... Full story

Yahoo Finance • 5 months ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 5 months ago

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif., December 18, 2025--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, infla... Full story

Yahoo Finance • 5 months ago

Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed. Continue Reading... Full story

Yahoo Finance • 7 months ago

Arcus Biosciences prices $250M offering

* Clinical-stage, global biopharmaceutical company Arcus Biosciences (RCUS [https://seekingalpha.com/symbol/RCUS]) priced [https://seekingalpha.com/pr/20287758-arcus-biosciences-announces-pricing-of-250-million-public-offering-of-common-... Full story

Yahoo Finance • 7 months ago

Sector Update: Health Care Stocks Advance Monday Afternoon

Health care stocks rose Monday afternoon, with the NYSE Health Care Index and the Health Care Select PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 months ago

Stocks making the biggest moves midday: Broadcom, Bloom Energy, Critical Metals, Fastenal and more

Check out some of the companies making the biggest moves midday: Broadcom -- The chipmaker jumped 10% after agreeing with OpenAI to jointly build and deploy custom artificial intelligence accelerators , the first public plan released by th... Full story

Yahoo Finance • 7 months ago

Arcus Biosciences rises on results from domvanalimab cancer study

[Cancer Anatomy] wildpixel/iStock via Getty Images * Arcus Biosciences (NYSE:RCUS [https://seekingalpha.com/symbol/RCUS]) rose after it reported results from mid-stage study of its monoclinical antibody domvanalimab with zimberelimab an... Full story

Yahoo Finance • 9 months ago

Arcus Biosciences’ SWOT analysis: stock’s potential hinges on HIF-2alpha data

Arcus Biosciences, Inc. (NASDAQ:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, has been garnering significant attention from investors and analysts alike. The company’s stock performance and future pr... Full story

Yahoo Finance • 10 months ago

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per share, beating the consensus of $1.94. Sal... Full story

Yahoo Finance • 10 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

PEAK-1, a Phase 3 study evaluating casdatifan + cabozantinib in immunotherapy (IO)-experienced ccRCC, and eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca evaluating casdatifan + volrustomig in first-line metastatic ccRCC, have be... Full story

Yahoo Finance • 10 months ago

Arcus Biosciences' SWOT analysis: HIF-2alpha program drives stock outlook

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its promising pipeline and recent developments... Full story

Yahoo Finance • 11 months ago

Arcus' pancreatic cancer drug quemliclustat receives FDA orphan status

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a biotechnology company with a strong balance sheet showing more cash than debt according to InvestingPro data, announced Thursday that its investigational CD73 inhibitor quemliclustat... Full story

Yahoo Finance • 11 months ago

Arcus Biosciences February 2025 slides: oncology pipeline progresses despite Q1 miss

Introduction & Market Context Arcus Biosciences (NYSE:RCUS) presented its corporate update on February 25, 2025, showcasing its oncology pipeline and development strategy. The presentation comes at a challenging time for the clinical-stag... Full story